A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, and the first COVID-19 vaccine candidate entered human clinical testing with unprecedented rapidity on 16 March 2020.
The global vaccine R&D effort in response to the COVID-19 pandemic is unprecedented in terms of scale and speed. Given the imperative for speed, there is an indication that vaccine could be available under emergency use or similar protocols by early 2021. This would represent a fundamental step change from the traditional vaccine development pathway, which takes on average over 10 years, even compared with the accelerated 5-year timescale for development of the first Ebola vaccine, and will necessitate novel vaccine development paradigms involving parallel and adaptive development phases, innovative regulatory processes and scaling manufacturing capacity.
According to our (Global Info Research) latest study, the global Covid-19 Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North America is the largest consumption place, with a consumption market share nearly 53.8% in 2026, Europe is the second largest consumption place with the consumption market share of 24.61% in 2026.
For more information (Including Full TOC, List of Tables & Figures, Chart), please click @ https://www.globalinforesearch.com/reports/994323/covid-19-vaccine
This report is a detailed and comprehensive analysis for global Covid-19 Vaccine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Market segment by Type
DNA
Non-replicating Viral Vector
Protein Subunit
RNA
Others
Market segment by Application
Adults
Children
Market segment by players, this report covers
Moderna
CanSino Biologicals
Inovio Pharmaceuticals
Shenzhen Geno-Immune Medical Institute
GlaxoSmithKine
Pfizer
Johnson＆Johnson
Heat Biologics
Sanofi
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for High Purity Covid-19 Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global High Purity Covid-19 Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, Chapter 1, to describe High Purity Covid-19 Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of High Purity Covid-19 Vaccine, with price, sales, revenue and global market share of High Purity Covid-19 Vaccine from 2018 to 2023.
Chapter 3, the High Purity Covid-19 Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the High Purity Covid-19 Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and High Purity Covid-19 Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of High Purity Covid-19 Vaccine.
Chapter 14 and 15, to describe High Purity Covid-19 Vaccine sales channel, distributors, customers, research findings and conclusion.
About US
Global Info Research is a report publisher, a customer, interest-based suppliers. Is in the best interests of our clients, they determine our every move. At the same time, we have great respect for the views of customers. With the improvement of the quality of our research, we develop custom interdisciplinary and comprehensive solution. For further development, we will do better and better. GlobalInfoResearch will with excellent professional knowledge and experience to carry out all aspects of our business. At the same time, we will thoroughly look for information, to give a more comprehensive development.
Contact US
Global Info Research
E-mail: report@globalinforesearch.com
Tel: +86-17665052062 00852-58197708(HK)
WeChat: 17665052062
Add:FLAT/RM A 9/F SILVERCORP INTERNATIONAL TOWER 707-713 NATHAN ROAD MONGKOK KL HONG KONG
Website: http://www.globalinforesearch.com
No comments:
Post a Comment